Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma

JACC Case Rep. 2021 Jun 2;3(7):1018-1023. doi: 10.1016/j.jaccas.2021.04.001. eCollection 2021 Jul 7.

Abstract

A 62-year-old woman with human T-lymphotropic virus type 1 cell lymphoma developed heart failure after mogamulizumab, an immunotherapy agent. Clinical presentation and cardiac magnetic resonance imaging were consistent with myocarditis, and a recurrence of heart failure occurred after rechallenge with the therapy. (Level of Difficulty: Advanced.).

Keywords: CCR4, C-X-C chemokine receptor type 4; CHOPE, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide; CMR, cardiac magnetic resonance; ECG, electrocardiogram; ICI, checkpoint inhibitor; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MR sequences; PE, pulmonary embolus; TTE, transthoracic echocardiogram; Treg, T regulatory cells; acute heart failure; cancer; cardiomyopathy.

Publication types

  • Case Reports